Anika Therapeutics, Inc. revised revenue guidance for the fiscal year 2023. For the year, the company raised its overall revenue outlook to be between $164 million to $166 million, representing growth of 5% to 6% compared to 2022, up from its previous range of $159.5 million to $163 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.59 USD | 0.00% | +7.90% | +21.76% |
Mar. 14 | Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating | MT |
Mar. 13 | Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.76% | 405M | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023